Table 2.
Primary and secondary outcomes for HIV-positive patients with CMVR treated at MTY Clinic, Myanmar, 2013–2017
| Total (N = 53) | Local treatment (N = 21) | Systemic treatment (N = 32) | P value | |
|---|---|---|---|---|
| Median (IQR) duration of treatment, daysa | 98 (55–172) | 63 (21–92) | 133 (80–195) | < 0.01 |
| Outcome, N (%) | 0.665 | |||
| Improvement | 7 (13) | 2 (10) | 5 (16) | |
| Stable | 30 (57) | 11 (52) | 19 (59) | |
| Deterioration | 3 (6) | 2 (10) | 1 (3.1) | |
| Deceased | 9 (17) | 5 (24) | 4 (12.5) | |
| Lost to follow up | 1 (1.9) | 0 (0) | 1 (3.1) | |
| Unknown | 3 (5.7) | 1 (5) | 2 (6.3) | |
| Worsening anaemia, N (%) | 20 (38) | N/A | 20 (63) | |
| CD4 count ≥100 cells/μL, N (%)b | ||||
| 3 months | 19 (36) | 9 (43) | 10 (31) | 0.170 |
| 6 months | 29 (55) | 11 (52) | 18 (56) | 1 |
| 12 months | 32 (60) | 9 (43) | 23 (72) | 0.571 |
CMVR Cytomegalovirus retinitis; IQR Interquartile range; MTY Mittar Yeik; N/A Not applicable.
a Excludes one patient treated with valganciclovir who was lost to follow-up.
b Excludes nine patients who died (no CD4 count from follow-up).